Ellen R. Rowley
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Menopause: Health Impacts and Treatments, Bone health and osteoporosis research, Bone Metabolism and Diseases, Bioactive Compounds and Antitumor Agents
Most-Cited Works
- → Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.(1994)612 cited
- → Structure−Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene(1997)175 cited
- → LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo(1998)133 cited
- → Synthesis and Pharmacology of Conformationally Restricted Raloxifene Analogues: Highly Potent Selective Estrogen Receptor Modulators(1998)126 cited
- → Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH(2002)68 cited
- → LY353381·HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1–34)(1998)45 cited
- → Raloxifene and Vitamin K2 Combine to Improve the Femoral Neck Strength of Ovariectomized Rats(2005)27 cited
- → Effects of Prolonged Ethinyl Estradiol Treatment on Calcium Channel Binding and In Vivo Calcium-Mediated Hemodynamic Responses in Ovariectomized Rats(1997)19 cited
- → Benzopyran selective estrogen receptor modulators (SERMs): Pharmacological effects and structural correlation with raloxifene(1996)17 cited
- → Synthesis and pharmacology of 2-alkyl raloxifene analogs(1996)13 cited